---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-046408"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:56:11.571559+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Incannex Healthcare PSX-001 aligns with Trump Executive Order accelerating psychedelic mental health treatments

## Summary
- White House Executive Order (April 18, 2026) directs FDA to prioritize psychedelic compounds with Breakthrough Therapy designations and creates Right to Try pathways.
- PSX-001 Phase 2 for GAD: 12.8-point HAM-A reduction vs 3.6 placebo (p<0.0001), 44% response rate, 27% remission rate, no serious adverse events.
- Company has over $70M cash, no debt; active U.S. IND; views Executive Order as reducing regulatory and commercial risk for psilocybin class.
- PSX-001 targets GAD affecting ~6.8M in U.S. and 280M globally; Phase 2 had single discontinuation across 73 patients.

## SEC filing metadata
- accession: 0001213900-26-046408
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026046408/0001213900-26-046408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026046408/ea0287297-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-046408
- JSON: https://secwatch.observer/filing/0001213900-26-046408.json
- Plain text: https://secwatch.observer/filing/0001213900-26-046408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.